Novartis — Cryptosporidiosis Challenge Trial
Verified$2.5M
Funder
Recipient
Novartis
Date
Oct 2024
Data source
Source
Notes
[Scientific Research] Open Philanthropy recommended a grant of $2,500,000 over two years to Novartis to support a Phase IIa challenge trial of a new drug, ED1048, for the treatment of cryptosporidiosis. Cryptosporidiosis is caused by the Cryptosporidium parasite. The parasite is widespread globally and highly resistant to sanitizers used for cleaning drinking water. The disease can be fatal in small children, the elderly, and immunocompromised people. This falls within our focus area of scientific research.
Other Grants by Coefficient Giving
2625| Grant | Recipient | Amount | Date |
|---|---|---|---|
| Janaagraha — Air Quality Grants Assessment | $195K | Dec 2024 | |
| Futurewise — Housing Advocacy in Washington | $450K | Apr 2023 | |
| Exscientia — Agonists for Interferon Lambda | $2.3M | Sep 2023 | |
| Kurzgesagt — Short-form Video Content | $3M | Mar 2022 | |
| Kurzgesagt — Video Production (2023) | $1.7M | May 2023 | |
| Kurzgesagt — Video Creation and Translation | $2.6M | Dec 2021 | |
| Lightcone Infrastructure – General Support | Lighthaven (Event Venue) | $4.5M | Sep 2022 |
| Lightcone Infrastructure — General Support (2023) | Lighthaven (Event Venue) | $3M | Oct 2023 |
| Conjecture — Cybersecurity Bootcamp | Conjecture | $223K | Jun 2025 |
| Conjecture — AI Safety Technical Program | Conjecture | $224K | May 2023 |
Showing 10 of 2625 grants